Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruth M de Tute

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
Histopathology|January 26, 2011
Flow cytometry and its use in the diagnosis and management of mature lymphoid malignanciesRuth M de Tute
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2013
Immunoglobulin M concentration in Waldenström macroglobulinemia: correlation with bone marrow B cells and plasma cellsRuth M de Tute, Andy C Rawstron, Roger G Owen
Cytometry. Part B, Clinical Cytometry|July 7, 2015
Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic ServiceAndy C Rawstron, Ruth M de Tute, J Haughton, et al.
Blood|June 19, 2014
Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysisQuentin A Hill, Andy C Rawstron, Ruth M de Tute, et al.
British Journal of Haematology|April 20, 2011
Translocation t(14;16) in IgM multiple myelomaRoger G Owen, Sheila J M O'Connor, Lee R Bond, et al.
American Journal of Hematology|July 16, 2011
Defining IgM multiple myelomaRoger G Owen, Sylvia Feyler, Sheila J M O'Connor, et al.
Blood|February 4, 2015
Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reductionAndy C Rawstron, Walter M Gregory, Ruth M de Tute, et al.
Haematologica|October 17, 2015
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimenRuth M de Tute, Andy C Rawstron, Walter M Gregory, et al.
Blood|March 10, 2021
Novel somatic mutations in UBA1 as a cause of VEXAS syndromeJames A Poulter, Jason C Collins, Catherine Cargo, et al.
British Journal of Haematology|November 22, 2018
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapseOliver C Cohen, Nicholas Counsell, Neil Rabin, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
Histopathology|January 26, 2011
Flow cytometry and its use in the diagnosis and management of mature lymphoid malignanciesRuth M de Tute
Clinical Lymphoma, Myeloma & Leukemia|March 26, 2013
Immunoglobulin M concentration in Waldenström macroglobulinemia: correlation with bone marrow B cells and plasma cellsRuth M de Tute, Andy C Rawstron, Roger G Owen
Cytometry. Part B, Clinical Cytometry|July 7, 2015
Measuring disease levels in myeloma using flow cytometry in combination with other laboratory techniques: Lessons from the past 20 years at the Leeds Haematological Malignancy Diagnostic ServiceAndy C Rawstron, Ruth M de Tute, J Haughton, et al.
Blood|June 19, 2014
Outcome prediction in plasmacytoma of bone: a risk model utilizing bone marrow flow cytometry and light-chain analysisQuentin A Hill, Andy C Rawstron, Ruth M de Tute, et al.
British Journal of Haematology|April 20, 2011
Translocation t(14;16) in IgM multiple myelomaRoger G Owen, Sheila J M O'Connor, Lee R Bond, et al.
American Journal of Hematology|July 16, 2011
Defining IgM multiple myelomaRoger G Owen, Sylvia Feyler, Sheila J M O'Connor, et al.
Blood|February 4, 2015
Minimal residual disease in myeloma by flow cytometry: independent prediction of survival benefit per log reductionAndy C Rawstron, Walter M Gregory, Ruth M de Tute, et al.
Haematologica|October 17, 2015
Minimal residual disease following autologous stem cell transplant in myeloma: impact on outcome is independent of induction regimenRuth M de Tute, Andy C Rawstron, Walter M Gregory, et al.
Blood|March 10, 2021
Novel somatic mutations in UBA1 as a cause of VEXAS syndromeJames A Poulter, Jason C Collins, Catherine Cargo, et al.
British Journal of Haematology|November 22, 2018
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapseOliver C Cohen, Nicholas Counsell, Neil Rabin, et al.
Pageof 2